Nodelman Oleg

DirectorAktis Oncology, Inc. (AKTS) · full profile →Form 4 · filed Jan 12, 2026
Net Buying
Open-Market Buys
$40.0M
Open-Market Sells
$0
Net Open-Market Flow
$40.0M
Transactions
12
5 non-derivative · 7 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 12, 2026Buy(P)2.1M$18.00$37.4M4.3M
Jan 12, 2026Conversion(C)129K129K
Jan 12, 2026Conversion(C)203K203K
Jan 12, 2026Conversion(C)2.3M2.3M
Jan 12, 2026Buy(P)144K$18.00$2.6M347K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 12, 2026Conversion(C)9.9M0
Jan 12, 2026Conversion(C)997K0
Jan 12, 2026Conversion(C)489K0
Jan 12, 2026Conversion(C)2.4M0
Jan 12, 2026Conversion(C)965K965K
Jan 12, 2026Conversion(C)86K86K
Jan 12, 2026Conversion(C)103K0

Transaction Codes

P
Open-market purchase
C
Conversion of a derivative

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000935836-26-000031) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

Build

Ask your agent about AKTS insider filings

This filing is the Follow view. The Build view lets your agent pull every Form 4 for the issuer, the net open-market picture over 90 days, and the accession behind each row, through REST or MCP.

Copy-paste
curl -H "Authorization: Bearer YOUR_API_KEY" \
  "https://arkolith.com/api/v1/filing/0000935836-26-000031"
Ask your agent
Use Arkolith to summarize insider buying and selling at Aktis Oncology, Inc.
over the last 90 days and cite the filings.